Sartorius Stedim Biotech S.A. (VIE:DIM)
| Market Cap | 15.79B -4.5% |
| Revenue (ttm) | 2.98B +4.4% |
| Net Income | 268.10M +31.2% |
| EPS | 2.76 +30.7% |
| Shares Out | n/a |
| PE Ratio | 58.90 |
| Forward PE | 30.46 |
| Dividend | 0.69 (0.37%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | n/a |
| Average Volume | n/a |
| Open | 159.90 |
| Previous Close | 158.90 |
| Day's Range | 159.90 - 161.70 |
| 52-Week Range | 157.35 - 222.60 |
| Beta | n/a |
| RSI | 39.58 |
| Earnings Date | Apr 23, 2026 |
About Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog... [Read more]
Financial Performance
In 2025, Sartorius Stedim Biotech's revenue was 2.97 billion, an increase of 6.74% compared to the previous year's 2.78 billion. Earnings were 265.60 million, an increase of 51.68%.
Financial StatementsNews
Sartorius Stedim Biotech SA (SDMHF) Q1 2026 Earnings Call Highlights: Strong Start with Robust ...
Sartorius Stedim Biotech SA (SDMHF) Q1 2026 Earnings Call Highlights: Strong Start with Robust Sales and Cash Flow Growth
Q1 2026 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Q1 2026 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Sartorius Stedim Biotech Earnings Call Transcript: Q1 2026
Sales and profitability grew in Q1 2026, driven by strong recurring business and innovations. Guidance for 2026 is confirmed, with robust cash flow, ongoing deleveraging, and positive biopharma market trends despite FX and geopolitical risks.
Sartorius Stedim Biotech Q1 Profit Rises On Revenue Growth; Confirms FY26 Outlook
(RTTNews) - Sartorius Stedim Biotech SA (SDMHF) reported Thursday higher profit and revenues in its first quarter. Further, the firm maintained its fiscal 2026 outlook.
Sartorius Stedim Biotech Transcript: AGM 2026
The meeting confirmed strong 2025 financial growth, approved all resolutions, and outlined strategic priorities in innovation, operational efficiency, and sustainability. Dividend of €0.71 per share was proposed, and auditors issued unqualified opinions. All agenda items passed with high shareholder participation.
Sartorius Stedim Biotech Transcript: CMD 2026
Ambitious midterm targets include 8%-11% organic revenue growth and margin expansion, driven by innovation in single-use technologies, AI, and advanced therapies. Regional growth is led by the U.S. and Asia, with operational excellence and customer experience as key priorities.
Sartorius Stedim Biotech Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 7.6% constant currency sales growth and EBITDA margin of 29.7%, driven by recurring business and operational leverage. 2026 guidance anticipates 5%-9% sales growth and margin above 30%, with continued investment in innovation and global capacity.
Sartorius Stedim Biotech Earnings Call Transcript: Q3 2025
Sales grew 7.5% in constant currencies to €2.6B, driven by strong consumables demand and margin expansion to 29.7%. BPS delivered double-digit growth, while LPS improved gradually. Full-year guidance was raised, with continued deleveraging and robust innovation pipeline.
Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing
AUBAGNE, France--(BUSINESS WIRE)-- #CGT--Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing.
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a...
Sartorius Stedim Biotech Earnings Call Transcript: Q2 2025
H1 2025 delivered 6% revenue growth and 12% EBITDA growth, led by strong consumables demand and margin expansion. BPS outperformed with 9% sales growth, while LPS remained challenged. Full-year guidance is confirmed, with higher confidence in BPS amid ongoing market uncertainties.
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform
AUBAGNE, France & BRATISLAVA, Slovakia--(BUSINESS WIRE)--Sartorius Stedim Biotech and Sensible Biotechnologies are scaling up a unique cell-based manufacturing platform for clinical-grade therapeutic ...
Sartorius Stedim Biotech Earnings Call Transcript: Q1 2025
Q1 2025 saw strong growth in consumables and recurring revenue, driving margin expansion and robust cash flow, while equipment sales remained soft. Guidance for 2025 anticipates 6% sales growth and a 29%-30% EBITDA margin, with tariff impacts being actively managed.
Sartorius Stedim Biotech Transcript: AGM 2025
The meeting covered board renewals, strong 2024 financials, and major global expansions. All resolutions, including dividend, board appointments, and sustainability initiatives, were approved. Key risks discussed included geopolitical uncertainties and market normalization.
Sartorius Stedim Biotech Earnings Call Transcript: Q4 2024
2024 results met revised guidance with flat sales and robust margins, driven by consumables growth and efficiency gains. Free cash flow doubled, leverage improved, and 2025 is expected to bring moderate, profitable growth above market rates, with continued focus on deleveraging.
Sartorius, Sartorius Stedim Biotech shares jump after results beat
Shares in Sartorius jumped 15.6% on Tuesday after the Franco-German lab supplies maker's preliminary annual results beat expectations and despite a cautious outlook for 2025.
Sartorius Stedim Biotech Earnings Call Transcript: Q3 2024
Nine-month 2024 results met expectations, with robust recurring business and strong order intake offsetting weak equipment sales. Profitability and cash flow improved, guidance for the year is confirmed, and efficiency programs are set to deliver significant savings in Q4.
Sartorius Stedim Biotech Earnings Call Transcript: Q2 2024
H1 results met sales and margin targets, but demand remains muted amid ongoing market volatility and post-pandemic normalization. Full-year guidance was de-risked to flat sales with a 27%-29% EBITDA margin, while efficiency programs and lower CapEx support financial stability.
Sartorius Stedim Biotech Transcript: CMD 2024
Sartorius Stedim Biotech Earnings Call Transcript: Q1 2024
Sartorius Stedim Biotech Transcript: AGM 2024
Sartorius Stedim Biotech Earnings Call Transcript: Q4 2023
10 stocks for investors looking for ‘wonderful companies at a fair price'
As money managers talk about various methods of selecting quality companies, investors might also think about diversification, which can lower risk and broaden opportunities.